With 2024 being an exceptional year for gold, Daniel Ghali, director of commodities strategy at TD Securities, explains ...

Bhawana Chhabra, senior market strategist at Rosenberg Research, explains how she expects the upcoming BoC rate decision will ...

Craig Moffett, senior research analyst at MoffettNathanson, explains why he's giving AT&T a neutral rating after the telecom giant reported positive Q4 earnings ...

One crypto expert expects the price of Bitcoin to roughly double by the end of the year due to more institutional capital ...

Monday’s tech rout gives investors yet another reason to buy bank shares, according to Wells Fargo analyst Mike Mayo.

Wall Street banks, finally within striking distance of offloading debt tied to X, have a sweetener on offer for potential ...

Paul MacDonald, CIO and portfolio manager at Harvest Portfolios Group Focus, shares his past picks; Stryker, Abbott ...

Andrew Cheng, president and CEO of Akero Therapeutics, discusses the findings of the pharmaceutical company's drug trial for EFX, a treatment for liver disease.

Paul MacDonald, CIO and portfolio manager at Harvest Portfolios Group Focus, shares his outlook on the market.

Geoff Kendrick, head of digital assets research at Standard Chartered, explains why investors shouldn't be scared off digital ...

Exchange-traded fund investors who placed record bets on the US technology space last week are getting crushed Monday as ...

Liberal leadership candidate Chrystia Freeland says she knows how to avoid punishing U.S. tariffs on Canadian goods: Scare ...